Hospitalization Provides An Opportunity For Sacubitril/valsartan Initiation

Sacubitril/valsartan reduces the risk of cardiovascular death and hospitalization when compared to enalapril, while providing a greater reduction in NT-proBNP and improved cardiac volume and function Additionally, it has shown to be safe to initiate in hospitalized patients Despite HFSA guideline recommendations to utilize sacubitril/valsartan as first line HF therapy, national utilization rates of 14% have been described Purpose: The purpose of this study is to identify barriers to initiation and continuation of sacubitril/valsartan in hospitalized HFrEF patients
Source: Journal of Cardiac Failure - Category: Cardiology Authors: Tags: 302 Source Type: research